Johannesburg - Pharmaceutical group Adcock Ingram Holdings [JSE:AIP] said on Monday it has acquired a controlling stake in Bioswiss.
Bioswiss specialises in human biosimilar insulins and a
range of diabetic diagnostic products such as Glucometer and test strips.
Adcock said the acquisition gave it an opportunity to become
a player in the diabetes market.
Dr Jonathan Louw, CEO of Adcock Ingram, said Bioswiss will
provide Adcock Ingram immediate entry into the growing diabetes market."
"The introduction of a biosimilar insulin range allows
us to provide a cost effective alternative for people living with
diabetes," he said.
"Bioswiss has been looking for a partner through which
to grow its business, and with Adcock as a strategic partner we will be able to
unlock the true potential of the product range," said Bioswiss CEO Dr Pieter Potgieter.
There are about six million in South Africans living with diabetes.